



October 11, 2022

Web Announcement 2917

Monkeypox Guidance and Technical Bulletins: Treatment, Pain Management and Severe Manifestations of Monkeypox

Since May 2022, more than 25,000 monkeypox cases have been identified in the United States. Patients with monkeypox benefit from supportive care and pain control that is implemented early in the illness. Illness depends on a person's immune response; for most patients with intact immune systems, supportive care and pain control may be enough.

However, because prognosis for monkeypox depends on multiple factors — such as initial health status, concurrent illnesses, previous vaccination history, and comorbidities — supportive care and pain control may not be enough for some patients (for example, those with weakened immune systems). In these cases, treatment should be considered. The Centers for Disease Control and Prevention (CDC) recently updated their [Interim Clinical Guidance for the Treatment of Monkeypox](#) and the Nevada Department of Health and Human Services issued a technical bulletin with details. [Visit the technical bulletins web page linked here](#) and see the “Monkeypox” section.